CHI3L1 Antibody (AMM10880A)
- Known as:
- CHI3L1 Antibody (AMM10880A)
- Catalog number:
- amm10880a
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- CHI3L1 Antibody (AMM10880A)
Related genes to: CHI3L1 Antibody (AMM10880A)
- Gene:
- CHI3L1 NIH gene
- Name:
- chitinase 3 like 1
- Previous symbol:
- -
- Synonyms:
- GP39, YKL40, YK-40
- Chromosome:
- 1q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-20
- Date modifiied:
- 2018-08-01
Related products to: CHI3L1 Antibody (AMM10880A)
Related articles to: CHI3L1 Antibody (AMM10880A)
- Various molecular biomarkers have been suggested as a method to improve the predictive value of prognosis in multiple sclerosis (MS). The characterization of such biomarkers would greatly enhance individual patient management. The aim of this study was to conduct a long-term, prospective evaluation of the prognostic value of molecular biomarkers in serum and cerebrospinal fluid (CSF) in patients in the early stages of MS, before the first treatment initiation. The study included a total of 121 MS patients. Serum and CSF were obtained during diagnostic process. Concentrations of IFN , IL-6, CHI3L1, osteopontin, CXCL13, GFAP and neurofilament light chains (NfLs) were analyzed. The mean time of the observation of clinical and radiological MS activity was 60 months after start of MS treatment. Higher serum concentrations of NfLs (Z = 2.28; = 0.02) and CXCL13 (Z = 2.14; = 0.03) correlated with need to change the first MS therapy (88% due to ineffectiveness and 12% due to adverse events). Higher NfLs concentrations in the CSF specifically correlated with the occurrence of radiological activity (Z = 2.02; = 0.04). Increased NfLs and IL-6 concentrations in the CSF correlated with disability progression assessed with the EDSS (Z = 2.81; Z = 2.87; = 0.004; = 0.003, respectively), as well as with clinical and/or radiological disease activity (Z = 2.80; Z = 2.43; = 0.004; = 0.014, respectively). High levels of NfLs and Il6 in the CSF of MS patients assessed before the therapy may be an indication to use a highly effective therapy as the first treatment for MS. - Source: PubMed
Publication date: 2026/03/31
Świderek-Matysiak MariolaOset MagdalenaPendrasik KarolinaŚwierczewska DominikaDomowicz MałgorzataNamiecińska MagdalenaStasiołek Mariusz - Cognitive dysfunction in multiple sclerosis (MS) has gained increasing attention over recent decades, reflecting its substantial effects on day-to-day functioning and the limited availability of targeted therapies. This review addresses contemporary advances in the role of cognition to detect disease progression, examines biological and MRI correlates of cognitive dysfunction, and summarizes the evidence for treatment effects. - Source: PubMed
Publication date: 2026/04/06
De Meo ErmelindaPortaccio EmilioAmato Maria Pia - Radiologically isolated syndrome (RIS) is characterised by incidental MRI findings suggestive of multiple sclerosis (MS) in individuals without typical MS symptoms. People with RIS (pwRIS) may have subtle manifestations, including cognitive impairment. We aimed to examine whether plasma chitinase 3-like 1 (pCHI3L1) levels in pwRIS are associated with cognitive impairment and grey matter volumes in regions known to be vulnerable in MS. - Source: PubMed
Publication date: 2026/04/06
Schneider RaphaelBrand-Arzamendi KoroboshkaLim Timothy ReynoldLee Lisa EunyoungGuenette MelanieHu ZixuanColak ErrolSuthiphosuwan SuradechBharatha AdityaFeinstein AnthonyOh Jiwon - Osteoarthritis (OA) is a widespread joint condition often linked to aging and obesity, resulting in pain, joint dysfunction, and disability. Betulin, a lupane-type pentacyclic triterpene alcohol extracted from birch trees, exhibits anti-inflammatory properties; however, its anti-inflammatory effects in OA remain largely unknown. Our high-throughput cytokine array data exhibit that betulin inhibits two key inflammatory factors, CHI3L1 and ICAM-1, in OA synovial fibroblasts (OASFs). Results from the GEO database and our clinical tissues confirm that CHI3L1 and ICAM-1 levels are markedly higher in OA patients compared to healthy individuals. Furthermore, anterior cruciate ligament transection (ACLT)-induced OA rats exhibited upregulated CHI3L1 and ICAM-1 expression. Mechanistically, we demonstrated that betulin inhibits CHI3L1 and ICAM-1 synthesis in OASFs by inhibiting the PI3K, Akt, and mTOR pathways and activating miR-5006-5p. Importantly, molecular docking analysis predicted an interaction between betulin with CHI3L1 and ICAM-1, suggesting its direct effects. Our investigation suggests that betulin is a leading candidate for OA management. - Source: PubMed
Publication date: 2026/03/17
Lee Kun-TsanTsai Chun-HaoWang Yu-HanHe Xiu-YuanFong Yi-ChinKo Chih-YuanTang Chih-Hsin - Cluster of differentiation 14 monocytes produced spindle-shaped fibrocytes, similar to fibroblasts. Recent studies have reported that fibrocytes are crucial for the development and progression of primary myelofibrosis (MF); however, their functional role remains unclear. We compared monocytes and fibrocytes using RNA sequencing for gene expression profiles. We focused on chitinase 3-like-1 (CHI3L1), which causes inflammation, organ fibrosis, and extracellular tissue remodeling. We found higher CHI3L1 levels in patients with myeloproliferative neoplasm with MF than in those without MF. Further, serum CHI3L1 levels were significantly associated with the presence of MF and splenomegaly in patients with lymphoid tumors. Romiplostim-induced MF in a mouse model demonstrated extensive bone marrow (BM) CHI3L1 mRNA expression, which was reversed by clodronate treatment. Two MF induction experiments on CHI3L1 mice, based on romiplostim or Janus kinase 2 mutations, revealed fewer reticular fibers in silver-stained BM slices than in wild-type mice. A culture assay revealed that high CHI3L1 concentrations promoted extracellular matrix production by fibroblast cell lines, and that a CHI3L1-neutralizing antibody abrogated this effect. These results indicate the importance of CHI3L1 in the association between fibrocytes and fibroblasts in MF and could be a focus for future treatment. - Source: PubMed
Kato ShoichiroKawamura ToshikuniMaekawa TakaakiOgata HirakuTachi NoriakiOsawa YukikoKobayashi Shinichi